Goldman Sachs’s Tandem Diabetes Care TNDM Stock Holding History

Goldman Sachs’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-27,200	Closed	-$1.15M	–	6266
2024 Q3	$1.15M	Buy	+27,200	New	+$1.15M	﹤0.01%	4539
2022 Q3	–	Sell	-26,500	Closed	-$1.57M	–	6533
2022 Q2	$1.57M	Hold	26,500	–	–	﹤0.01%	4261
2022 Q1	$3.08M	Buy	+26,500	New	+$3.09M	﹤0.01%	3833
2016 Q2	–	Sell	-4,700	Closed	-$409K	–	7255
2016 Q1	$409K	Buy	+4,700	New	+$411K	﹤0.01%	4956
2015 Q4	–	Sell	-5,840	Closed	-$515K	–	7340
2015 Q3	$515K	Buy	+5,840	New	+$680K	﹤0.01%	5112
2015 Q1	–	Sell	-10,000	Closed	-$1.27M	–	7286
2014 Q4	$1.27M	Buy	+10,000	New	+$1.39M	﹤0.01%	4311

Other funds holding TNDM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Goldman Sachs's TNDM Position: Q2 2026 in Review

Goldman Sachs reduced its Tandem Diabetes Care (TNDM) stake by 61% in Q2 2026, selling an estimated $23.7M and leaving 862,301 shares worth $13M. The position accounts for ﹤0.01% of the portfolio, ranked #3025.

Goldman Sachs first reported a position in TNDM in Q4 2013 and has held it in 41 quarters since. The position peaked at $140M in Q4 2021. 274 funds tracked by Wall St. Rank hold TNDM as of Q2 2026.

Goldman Sachs held 862,301 shares of Tandem Diabetes Care worth $13M as of Q2 2026.
Goldman Sachs sold 1,356,621 Tandem Diabetes Care shares in Q2 2026, an estimated $23.7M.
Tandem Diabetes Care made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3025 holding.
Goldman Sachs first reported a position in Tandem Diabetes Care in Q4 2013 and has held it in 41 quarters since.
Goldman Sachs's Tandem Diabetes Care position peaked at $140M in Q4 2021.
274 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.